Physician profile

Daniel A Small

Obstetrics & Gynecology · Lawrenceville, NJ

NPI 1528030186

$19,170.53

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$32.97

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $18,973.83 2019-2023
Bayer Healthcare Pharmaceuticals INC. $41.59 2019
Amag Pharmaceuticals, INC. $26.54 2019
Exeltis, USA INC. $25.69 2019-2020
Covidien Lp $20.64 2019
Abbvie INC. $14.92 2019
Therapeuticsmd, INC. $14.61 2019
Duchesnay USA Incorporated $14.49 2019
Allergan, INC. $13.70 2019
Millicent US INC $13.38 2019
Coopersurgical, INC. $11.14 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel A Small

$19,170.53

in general payments reported 2019-2025

Years
2019-2023
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/159800/daniel-a-small

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.